Related Experiment Video
Updated: Mar 20, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
[Combined Therapy with Targeted Drugs in Lung Cancer]
1Dept. of Medical Oncology, Cancer Research Institute, Kanazawa University.
Abstract:
As targeted therapies for lung cancer, EGFR tyrosine kinase inhibitors(EGFR-TKIs)and ALK-TKIs have been approved for EGFR mutation-positive advanced non-small cell lung cancer(NSCLC)and ALK-fusion gene-positive advanced NSCLC, respectively. Very recently, an anti-immune checkpoint antibody was approved for advanced or recurrent NSCLC. In this article, the current status of combined therapy is reviewed with a focus on EGFR-TKIs, which are the most frequently used targeted therapies in clinical practice for lung cancer. To increase the efficacy of EGFR-TKIs in EGFR-mutant NSCLC, a large number of clinical trials using EGFR-TKIs and other agents, such as cytotoxic chemotherapy, angiogenesis inhibitors, or antiimmune checkpoint antibodies, are being conducted. On the other hand, several trials have also been conducted to examine the efficacy of EGFR-TKIs in adjuvant settings for earlier staged EGFR-mutant NSCLC. Based on the results of these trials, a paradigm shift concerning treatment with targeted therapy for EGFR-mutant NSCLC is possible in the future.
Insights
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are key for EGFR-mutant non-small cell lung cancer (NSCLC). Research explores combining EGFR-TKIs with chemotherapy, angiogenesis inhibitors, or immunotherapy to improve lung cancer treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
Context:
- Targeted therapies like EGFR tyrosine kinase inhibitors (EGFR-TKIs) and ALK-TKIs are established treatments for specific non-small cell lung cancer (NSCLC) subtypes.
- Recent approvals include immune checkpoint antibodies for advanced or recurrent NSCLC, expanding therapeutic options.
Purpose:
- To review the current status of combination therapies for lung cancer, with a specific focus on EGFR-TKIs.
- To explore strategies for enhancing the efficacy of EGFR-TKIs in EGFR-mutant NSCLC through combination treatments and adjuvant settings.
Summary:
- Numerous clinical trials are investigating the combination of EGFR-TKIs with cytotoxic chemotherapy, angiogenesis inhibitors, and anti-immune checkpoint antibodies to improve treatment outcomes in EGFR-mutant NSCLC.
- Clinical trials are also evaluating the efficacy of EGFR-TKIs in adjuvant settings for earlier stages of EGFR-mutant NSCLC.
Impact:
- Findings from ongoing trials may lead to a paradigm shift in the treatment of EGFR-mutant NSCLC, potentially improving patient survival and treatment efficacy.
- The review highlights the evolving landscape of lung cancer therapy, emphasizing the role of combination strategies and targeted treatments.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:27Tumor Immunotherapy